论文部分内容阅读
目的 探讨转化生长因子 β1(TGF β1)及其Ⅰ、Ⅱ型受体 (TGFR1,TGFR2 )对白血病预后的意义。方法 采用SABC免疫组织化学方法观察TGF β1及TGFR1,TGFR2 在急性白血病患者的表达情况 ,并用ELISA法测定白血病患者血清及骨髓TGF β1水平。结果 白血病细胞TGF β1表达水平与对照组比较差异无显著性 (P >0 .0 5)。初诊患者的TGFR1及TGFR2 表达水平非常显著低于对照组 (P <0 .0 1) ,急性非淋巴白血病 (ANLLL)和急性淋巴白血病 (ALL)之间差别无显著性 (P >0 .0 5)。经治疗达完全缓解 (CR)后 ,这 2型受体的表达水平上升至接近正常 ,病情复发时则又降低。结论 TGF β1及其Ⅰ、Ⅱ型受体水平的测定有助于判断白血病的预后。
Objective To investigate the significance of transforming growth factor β1 (TGFβ1) and its type I and II receptors (TGFR1, TGFR2) in the prognosis of leukemia. Methods SABC immunohistochemistry was used to observe the expression of TGFβ1, TGFR1 and TGFR2 in patients with acute leukemia. Serum and bone marrow TGF β1 levels were measured by ELISA. Results There was no significant difference in the expression of TGF β1 between leukemia cells and the control group (P > 0.05). The levels of TGFR1 and TGFR2 in the newly diagnosed patients were significantly lower than those in the control group (P < 0.01). There was no significant difference between acute non-lymphoid leukemia (ANLLL) and acute lymphoblastic leukemia (ALL) (P > 0.05). ). After treatment for complete remission (CR), the expression level of these type 2 receptors rose to near normal, and when the disease relapsed, it decreased again. Conclusion The determination of TGFβ1 and its type I and type II receptors can help determine the prognosis of leukemia.